In a report issued on October 14, Andy Hsieh from William Blair reiterated a Buy rating on Pfenex (PFNX). The company’s shares closed last Monday at $9.18, close to its 52-week high of $10.20.
Hsieh has an average return of 38.7% when recommending Pfenex.
According to TipRanks.com, Hsieh is ranked #3737 out of 5556 analysts.
Pfenex has an analyst consensus of Moderate Buy, with a price target consensus of $19.00, an 118.4% upside from current levels. In a report issued on October 7, JMP Securities also maintained a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
Based on Pfenex’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.63 million. In comparison, last year the company had a GAAP net loss of $10.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfênex, Inc. is a clinical-stage biotechnology company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes biosimilars and vaccines. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.
